Monte Rosa Therapeutic (GLUE) Q4 2025 earnings summary

Executive summary

• Positive interim Phase 1 data for NEK7-directed MGD MRT-8102 showed significant CRP reductions in subjects at elevated cardiovascular risk, with further readouts expected in H2 2026.

• MRT-8102 demonstrated a favorable safety profile in SAD/MAD cohorts, with no serious adverse events and a broad therapeutic window.

• Multiple Phase 2 studies for MRT-8102 are planned in CVD risk, gout flares, and hidradenitis suppurativa, starting H2 2026 through H1 2027.

• MRT-2359 in combination with enzalutamide showed a 100% PSA response rate in mCRPC patients with AR mutations; Phase 2 study with apalutamide to begin Q3 2026.

• VAV1-directed MGD MRT-6160 is advancing toward multiple Phase 2 studies in immune-mediated diseases in collaboration with Novartis.

Financial highlights

• Collaboration revenue for Q4 2025 was $2.8M (down from $60.6M in Q4 2024); full-year 2025 revenue was $123.7M (up from $75.6M in 2024).

• R&D expenses for Q4 2025 were $42.0M (up from $38.9M in Q4 2024); full-year R&D expenses were $141.5M (up from $121.6M in 2024).

• Net loss for Q4 2025 was $46.1M (vs. $13.4M in Q4 2024); full-year net loss was $38.6M (improved from $72.7M in 2024).

• Cash, cash equivalents, and marketable securities totaled $382.1M as of Dec 31, 2025.

• $345M upsized follow-on financing in January 2026 further strengthened the balance sheet.

Outlook and guidance

• Cash runway expected to fund operations and capital expenditures into 2029.

• Anticipated readout of GFORCE-1 study for MRT-8102 in H2 2026; multiple Phase 2 studies to initiate from H2 2026 through H1 2027.

• Phase 2 study of MRT-2359 with apalutamide in mCRPC to start in Q3 2026.

• IND submission for cyclin E1-directed MGD and second-generation NEK7-directed MGD planned for 2026.